This item requires a subscription to Molecular Cancer Therapeutics.
Full Text (PDF)
To view this item, select one of the options below:
Sign In
Purchase Short-Term Access
- Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00.
- Pay for Admission - You may access all content in Molecular Cancer Therapeutics (from the computer you are currently using) for 1 day for US$50.00.
- Regain Access - You can regain access to a recent Pay per Article or Pay for Admission purchase if your access period has not yet expired.
Sign Up
- Subscribe to the Journal - Subscribe to the print and/or online journal.
This Article
-
Mol Cancer Ther July 1, 2009 8, 1974
- Show PDF in full window
- AbstractFree
- Full Text
- » Full Text (PDF)
- Supplementary Materials, Hoang et al
Classifications
Services
Citing Articles
Google Scholar
Most
-
Read
- Antisense Oligonucleotides: Basic Concepts and Mechanisms
- Marine natural products as anticancer drugs
- Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
-
Cited
- The Role of the Cyclin-dependent Kinase Inhibitor p21 in Apoptosis
- Constitutive and Inducible Akt Activity Promotes Resistance to Chemotherapy, Trastuzumab, or Tamoxifen in Breast Cancer Cells
- The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo
- Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C
- SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor {beta} in Preclinical Models of Human Small Cell Lung Cancer